Definium Therapeutics Prices $700 Million Upsized Public Offering on June 24, 2026 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene commercialization Definium Therapeutics development aspects DFTX DT120 ODT Jefferies Leerink Partners public entity research securities working capital +